Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 3;15(6):4005–4014. doi: 10.3892/mmr.2017.6546

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Yan et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — SFN attenuates BLM-induced lung alveolitis. (A) Hematoxylin and eosin staining of lung tissues at 7 and 28 days following SFN treatment. BLM induced lung alveolitis, which was attenuated by SFN treatment. Magnification, ×200. (B) The Szapiel alveolitis score was lower in the BLM/SFN group, compared with the BLM group at day 7 and 28. (C) Western blot analysis for TNF-α and IL-1β protein expression levels was used to investigate the effect of SFN on BLM-induced lung alveolitis at day 7 and 28 post-treatment. Data are presented as the mean ± standard deviation (n=6/group). ^#P<0.05 vs. control group; *P<0.05 vs. BLM group. BLM, bleomycin; SFN, sulforaphane; TNF-α; tumor necrosis factor-α, IL-1β, interleukin-1β; Ctrl, control.